VOCABRIA DIN 02497204
Status: Marketed
Holder: VIIV HEALTHCARE ULC
Molecule: CABOTEGRAVIR (CABOTEGRAVIR SODIUM)
Available to quote
Health Canada record
| Active ingredient(s) | CABOTEGRAVIR (CABOTEGRAVIR SODIUM) 30 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AJ04 CABOTEGRAVIR |
| Original market date | 21-Sep-2020 |
| Current status date | 21-Sep-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
ViiV Healthcare ULC — licence 101800, currently licensed, last inspection rating C (2025-09-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CABOTEGRAVIR (CABOTEGRAVIR SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02547465 | APRETUDE | VIIV HEALTHCARE ULC | Tablet | CABOTEGRAVIR (CABOTEGRAVIR SODIUM) 30 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23362 | 2020-03-18 | New Drug Submission (NDS) |